4.5 Article

Angiotensin receptor blockade and stereotactic body radiation therapy for early stage lung cancer ARB & SBRT for early stage lung cancer

期刊

CANCER BIOLOGY & THERAPY
卷 23, 期 1, 页码 1-8

出版社

TAYLOR & FRANCIS INC
DOI: 10.1080/15384047.2022.2126250

关键词

Non-small cell lung cancer (NSCLC); stereotactic body radiation therapy (SBRT); angiotensin receptor blocker (ARB); tumor growth factor beta (TGF-beta)

类别

资金

  1. National Cancer Institute [K08 CA245188]
  2. Knight Cancer Institute

向作者/读者索取更多资源

This study investigates whether patients taking angiotensin receptor blockers (ARBs) during stereotactic body radiotherapy (SBRT) for early stage lung cancer experience improved overall survival (OS) or recurrence-free survival (RFS). The results show that patients taking ARBs during SBRT exhibited increased OS and RFS compared to patients not taking ARBs. However, the use of angiotensin converting enzyme inhibitors (ACEIs) or statins did not show the same effect.
Stereotactic body radiotherapy (SBRT) demonstrates excellent local control in early stage lung cancer, however a quarter of patients develop recurrence or distant metastasis. Transforming growth factor-beta (TGF-beta) supports metastasis and treatment resistance, and angiotensin receptor blockade (ARB) indirectly suppresses TGF-beta signaling. This study investigates whether patients taking ARBs while undergoing SBRT for early stage lung cancer exhibited improved overall survival (OS) or recurrence free survival (RFS) compared to patients not taking ARBs. This was a single institution retrospective analysis of 272 patients treated with SBRT for early stage lung cancer between 2009 and 2018. Patient health data was abstracted from the electronic medical record. OS and RFS were assessed using Kaplan-Meier method. Log-rank test was used to compare unadjusted survival between groups. Univariable and multivariable Cox proportional hazard regression models were used to estimate hazard ratios (HRs). Of 247 patients analyzed, 24 (10%) patients took ARBs for the duration of radiotherapy. There was no difference in mean age, median tumor diameter, or median biologic effective dose between patients taking ARBs or not. Patients taking ARBs exhibited increased OS (ARB = 96.7 mo.; no ARB = 43.3 mo.; HR = 0.25 [95% CI: 0.10 to 0.62, P = .003]) and increased RFS (median RFS, ARB = 64.3 mo.; No ARB = 35.1 mo.; HR = 0.26 [95% CI: 0.10 to 0.63, P = .003]). These effects were not seen in patients taking angiotensin converting enzyme inhibitors (ACEIs) or statins. ARB use while undergoing SBRT for early stage lung cancer may increase OS and RFS, but ACEI use does not show the same effect.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据